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Abstract 
Background 
Lifestyle weight management interventions are recommended in clinical guidelines for patients with 
type 2 diabetes and obesity, but lack evidence regarding their long term effectiveness. 
Materials and Methods 
Electronic health records were used to follow 23,208 patients with type 2 diabetes and obesity in 
Glasgow, Scotland, for up to 3 years between 2005 and 2014. Patients were stratified by referral to 
and attendance at a lifestyle weight management intervention, and by attainment of a target weight 
loss of ≥5kg over 7-9 sessions (“successful completers”). Outcomes were change in weight, HbA1c, 
and diabetes medications. 
Results 
3471 potentially eligible patients were referred to the service, and less than half of those attended 
(n=1537). Of those who attended 7-9 sessions, >40% successfully completed with a 5kg weight loss 
(334/808).  Successful completers maintained greater weight loss (change at 3 years -8.03kg; 95%CI -
9.44;-6.62) than the non-completers (-3.26kg; 95%CI; -4.01;-2.51; p<0.001) and those not referred to 
the service (-1.00kg; 95%CI -1.15;-0.85; p<0.001). Successful completers were the only patient group 
who did not increase their use of diabetes medication and insulin over 3 years. In adjusted models, 
successful completers had a clinically significant reduction in HbA1c ((-3.7mmol/mol; 95%CI -5.82;-
1.51) after 3 years; p≤0.001) compared to non-completers and unsuccessful completers.  
Conclusions 
A real-life structured weight management intervention in patients with diabetes can reduce weight in 
the medium term, result in improved glycaemic control with fewer medications, and may be more 
effective than pharmacological alternatives. Challenges include getting a higher proportion of patients 
referred to and engaged with interventions. 
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Introduction  
Obesity is a major risk factor for type 2 diabetes(1) and consequently the majority of adults with type 2 
diabetes (T2DM) in Scotland have a body mass index (BMI) greater than 30kg/m2(2). The risk of 
mortality in patients with type 2 diabetes increases with increasing BMI above 30kg/m2(3–5). 
International diabetes guidelines recommend that weight loss interventions should be prescribed to 
patients with coexisting type 2 diabetes and obesity, aiming for an initial 5-10% (typically a 5-10kg) 
weight loss(6–8). However there are barriers to implementing this guidance in practice , including a 
lack of funded services(9–11). 
A lack of an evidence base for the longer term clinical outcomes of non-surgical weight management 
in type 2 diabetes is a major barrier to both the public and insurance-based funding of suitable 
services(11,12). The LookAHEAD(13) randomised controlled trial included 5145 participants with type 2 
diabetes, who were assigned to an intensive lifestyle intervention or to three sessions of diabetes 
support and education. The intervention was far more intensive than support generally available to 
patients with type 2 diabetes in the community, and included near weekly individual or group sessions 
for a year, monthly sessions for the subsequent four years, along with optional meal replacements and 
a focus on high levels of supported physical activity. The results were impressive with an 8.5% 
weight loss and 7mmol/mol reduction in HbA1c after one year, attenuating to 4.7% and 2mmol/mol 
after four years(13). However, selection bias is a potential issue for such an intensive trial with an entry 
criterion that included the ability to perform an exercise test; this may have resulted in a healthier and 
more adherent cohort than is seen in routine clinical care. 
There is therefore an urgent need to improve the evidence base for the longer term clinical outcomes 
of real-life non-surgical lifestyle weight management interventions in patients with type 2 diabetes. 
Evaluations of existing services(14–18) have shown modest results with a minority of patients achieving 
clinically significant short term weight loss. However, these interventions are low cost and low risk, 
with negligible ongoing costs if non-responding patients discontinue. It follows that if these 
interventions are effective in improving clinical outcomes in type 2 diabetes for those that do 
successfully lose weight, then they should become a much greater part of usual care with investment 
in research to improve uptake and success.  
This study will answer the questions 1) whether a sustainable non-surgical weight management 
intervention helps patients achieve a long term 5-10% weight loss and 2) whether such weight loss 
improves glycaemic control and 3) whether such weight loss reduces anti-glycaemic medication use. 
The clinical outcomes from non-surgical weight management in the general diabetes patient 
population will be established by utilising data from a large multi-disciplinary weight management 
programme and routine diabetes care records. The use of routine data allows efficacy for longer term 
clinical outcomes to be established beyond the length of the weight management intervention, 
including the effect on glycaemic control and medication usage, while highlighting the important 
issues of uptake and adherence.  
Methods 
The National Health Service Greater Glasgow and Clyde (NHS GGC) health board area, Scotland, 
covers a population of almost 1.15 million people. A cohort of all patients who resided in NHS GGC 
and had type 2 diabetes was created from routine diabetes patient care records (Scottish Care 
Information Diabetes Collaboration [SCI-Diabetes]). SCI-Diabetes is a Scottish population-based 
clinical information system, containing demographic and clinical data from patients that have been 
diagnosed with diabetes. This register includes data from all but five of over 1000 general practices in 
Scotland and was shown to detect 99.4% of patients with diabetes in Scotland. 
These diabetes data were then combined with patients’ records from NHS GGC Weight Management 
Service (GCWMS), using the Community Health Index (CHI) number. The CHI number is unique to 
each individual patient and used for every healthcare interaction, allowing record linkage. As a result, 
clinical data for weight management in patients with type 2 diabetes were generated alongside a 
cohort of all patients with type 2 diabetes who lived within the GCWMS catchment area but had not 
been referred to the service. Data were accessed via the NHS Greater Glasgow and Clyde Safe Haven 
which allowed access to data, with patient identifiers removed, via a virtual private network. NHS 
GGC Safe Haven acts as the Local Privacy Advisory and ethical review committee for this research 
and granted ethical approval and data access for this study.  
The GCWMS intervention, which was developed in 2004, is a time-limited structured educational 
lifestyle programme employing cognitive behavioural therapy techniques alongside a 600 kcal deficit 
diet and physical activity advice for patients with complex obesity that are 18 years or older(19). It is 
delivered as part of the National Health Service and is free of charge to all patients with type 2 
diabetes, a BMI ≥30kg/m2 and who reside in the health board area. Referrals to GCWMS are made by 
general practitioners or hospital doctors, providing patients with the choice to opt-in (by telephoning 
the service) to be assessed and thereafter to attend the first session. Records of each assessment and 
visit are kept electronically, linked by the patient’s CHI number, thereby minimising missing data. 
Phase 1 of the intervention includes nine 90 min sessions delivered fortnightly over a 16-week period 
in groups of up to 16 participants. It is delivered in a range of hospital and community venues. Upon 
completion of phase 1, patients can choose to enter phase 2, which consists of four 1-h group sessions 
delivered at monthly intervals and includes a range of treatment options including further lifestyle 
advice or a prescribed structured low-calorie diet or pharmacotherapy (orlistat). At the end of phase 2, 
or directly from the end of phase 1, dependent on patient choice, patients enter a weight maintenance 
programme (phase 3) comprising 12 1-h group sessions delivered at monthly intervals. Patients who 
fail to achieve the target weight loss of 5kg can choose to repeat phase 2 once more and then enter the 
maintenance programme. If patients fail to lose 5kg, and have a BMI ≥40kg/m2 or a BMI ≥35kg/m2 
with comorbidities, they can opt to be considered for bariatric surgery. Overall the complete 
programme represents 43 hours of contact time with a dietician, delivered in groups of 12. 
Participants are regrouped each phase to account for drop-outs and the programme therefore totals 
3.6h of dietician contact time per participant.  
Data handling 
Data handling and exclusions are summarised in figure 1.  All biochemical data were measured by 
routine NHS clinical laboratories. Where multiple values were recorded within a specific time 
window, the chronologically earliest was used. For those who were referred, if no weight data were 
recorded for a specific session, it was regarded as “not attended” for that session. Specific details on 
data handling for patients referred to, and those not referred to GCWMS can be found in 
supplementary material. 
Group definitions in the patients referred to GCWMS 
Those who attended at least one session were labelled “attenders” (Fig 1). Attenders were further 
divided into “non-completers” (those who attended 1-6 sessions within phase 1) and “completers” 
(those who attended at least 7/9 [80%] of the sessions within phase 1). We classified “unsuccessful 
completers” as those who attended at least 80% of sessions, but did not lose 5kg (this was the 
definition used within the service and therefore affected the subsequent intervention), while 
“successful completers” attended at least 80% of sessions and achieved at least 5kg weight loss by the 
end of Phase 1.  
Statistical analyses 
We compared reported means and standard deviations (for Gaussian variables), medians and inter-
quartile ranges (for non-Gaussian continuous variables), and proportions where appropriate. We 
conducted tests of the null hypothesis between groups with independent t-tests, ranks sum tests, and 
χ2 tests, respectively. Differences in continuous variables across time were assessed by taking the 
difference in individual measurements and conducting a one sample t-test. Difference in insulin use 
was defined as the net change in the proportion using insulin at different time-points. Weight loss 
targets are often set at 5% (instead of 5kg in GCWMS). Thus, for the sake of comparability, we 
additionally used a cut point of 5% of initial weight and reported three-year change in HbA1c in these 
groups, thereby exploring the independent effect of the intention to treat in the GCWMS programme 
on glycaemic control.  
To assess the effectiveness of successful completion of the GCWMS programme on clinical 
outcomes, we further performed a multivariable linear regression analysis with successful completion 
(non- and unsuccessful completers vs successful completers) as the predictor variable and either 
weight, HbA1c or unique diabetes medications used at each time point, as the outcome variable, with 
adjustment for potential confounding variables. Similarly, logistic regression was conducted with 
insulin use as the outcome. 
A value of p≤0.05 was considered statistically significant. The method of analysis and reporting is 
specified in the footnote of each table. All data handling and analyses were performed using Stata®SE 
v12.1 (Stata Corporation) and IBM® SPSS® Statistics v22 (IBM Corporation) statistical software 
packages. 
Role of the funder: SB was visiting the University of Glasgow on a travel fellowship funded by 
North-West University Research Development Grant; they had no role in the conduct of this research 
Data sharing: the data used for this study are available to bona fide researchers via NHS Greater 
Glasgow and Clyde Safe Haven (http://www.nhsggc.org.uk/about-us/professional-support-
sites/nhsggc-safe-haven/) 
Results 
Baseline characteristics by GCWMS status 
We identified 23,208 patients with type 2 diabetes and co-existent obesity, with the required routine 
data for inclusion, residing in the Greater Glasgow and Clyde Health Board area of Scotland, and all 
potentially eligible to attend GCWMS. In total, 3471 were referred to the service, and of these 1537 
attended at least one session (44.3%), with 808 (23.3%) attending ≥7 sessions (“completers”). Of 
these, 336 patients (“successful completers”) went on to lose 5kg in phase one of the programme 
(9.7% of all those referred) (Fig 1). 
The baseline characteristics of 19,737 patients who were not referred to GCWMS, and 3471 who were 
referred and attended the service are shown in table 1. Those referred and attending were generally 
slightly younger and were more likely to be female, white, and were less likely to be 
socioeconomically deprived (with 14.8% being in the least deprived quintile (Q5) of SIMD compared 
to 12.1% of those not referred). The BMI of those who were referred and attended was higher than 
those not referred (medians 38.5 vs 33.9kg/m2) with 56.8% of those referred and attaining having a 
BMI ≥40kg/m2. Among those referred, glycaemic control was poorer than among those not referred 
(HbA1c median 57 vs 56 mmol/mol), reflecting a greater duration of diabetes, and a higher number of 
unique diabetes medications (mean and standard deviation 1.5 ± 1.1 vs 1.3 ± 1.0), although insulin use 
was similar. 
Those attending the service were categorised as completers if they completed ≥80% of lifestyle 
sessions and success is defined as 5kg weight loss by the end of the lifestyle phase. Of those referred 
and attending, 808/1537 (56.6%) completed the lifestyle phase, with 334/808 (41.3%) of completers 
(21.7% of those referred and attending) being defined as successful (table 2). The only significant 
difference between those individuals successfully completing compared to those that were 
unsuccessful completers, was a higher initial weight in those who were successful (116.6kg ±24.8 vs 
113.2kg ±23.1; p=0.045). 
Changes in clinical variables over follow-up by GCWMS status 
All comparator groups lost weight within the first year but successful completers had the greatest 
weight loss after one year (-8.66 kg, 95% CI -9.59 to -7.74) and maintained this weight loss with 
weight change at year three, relative to baseline, of -8.03kg (95% CI -9.44 to -6.62) (Table 3, Fig 2).  
Successful completers improved their glycaemic control in comparison to the other groups over the 3 
years (Table 3, Fig 2). HbA1c decreased the most compared to baseline after one year in the 
successful completers (-7.19mmol/mol, 95% CI -8.83 to -5.55). Non-completers had an increased 
HbA1c after 3 years when compared to baseline (2.02mmol/mol [95% CI 0.40 to 3.63]), and those not 
referred to GCWMS also had a slight increase in HbA1c (0.35mmol/mol [95% CI 0.10 to 0.59]). By 
contrast, HbA1c in successful and unsuccessful completers was comparable to baseline at 3 years. 
The number of unique diabetes medications used increased gradually over three years in every group 
except successful completers (Table 3, Supp fig 1). For example, at year 3 those not referred had an 
increased mean number of unique diabetes medications (0.33 [95% CI 0.32 to 0.34]), as did 
unsuccessful completers (0.39 [95% CI 0.29 to 0.48]), yet successful completers had no change in the 
number of unique diabetes medications (0.04 [95% CI -0.07 to 0.14]). In general, the trend was 
towards an increasing use of insulin over time in most groups, but insulin use did not change over 3 
years of follow-up in the successful completers (Table 3; Fig 3). 
The effect of attending the GCWMS programme and successfully losing 5kg, compared to non-
completers and unsuccessful completers, adjusted for age, sex, ethnicity, SIMD, time since type 2 
diabetes diagnosis, baseline HbA1c, weight, BMI, diabetes medication use and insulin use, is shown 
in table 4. Successful attenders in GCWMS had a number of metabolic and clinical benefits over 3 
years, including greater sustained weight loss, a greater improvement in glycaemic control, and use of 
fewer diabetes medications compared to non-completers and unsuccessful completers. Those who lost 
5kg in GCWMS were >50% less likely to have been prescribed insulin at 1 and 2 years, although the 
effect was not significant at 3 years.  Similar results were seen for the prescription of dipeptidyl 
peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, with successful completers 
around 50% less likely to have been prescribed these medications at 3 years compared to unsuccessful 
and non-completers (supplement table 1). 
In order to explore the GCWMS-specific effect of weight loss on HbA1c, the effect of 5% weight loss 
on change in HbA1c over 2 years, compared to baseline, was assessed within each of the GCWMS 
groups (not referred, non-completers and completers), adjusted for potential confounding variables 
(Table 5). The effect of 5% weight loss on change in HbA1c over 2 years was significant within each 
group but was largest in those who completed the programme (-2.49, 95%CI -3.53; -1.46; p<0.001). 
The test for interaction comparing the effect of weight loss on HbA1c across groups was highly 
significant (p<0.001). 
Time spent in the weight management programme and changes in weight in both phase 1 and the 
whole programme, by completion status is shown in Table 6. Those who successfully completed 
phase 1 eventually spend 11.9 months (IQR 7.1-17.3) in the programme and lost an average of 9.9kg 
±8.24kg by their final visit. 
Discussion 
In this large study of patients with type 2 diabetes and obesity, using a real world data from a 
sustainable structured weight management intervention, we show those who attend and lose at least 
5kg in the first 16 weeks maintain that weight loss over 3 years. Patients who successfully lose 5kg in 
the programme also have an independent, clinically significant, reduction in HbA1c (6.6, 5.7, and 
3.7mmol/mol at year 1, year 2, and year 3, respectively) compared to non-attenders and unsuccessful 
attenders. Successful completers of the weight management programme have a reduction in number 
of diabetes medications and less of them progress to requiring insulin. However, only a small number 
of potentially eligible patients were referred, and less than half of those referred actually attended the 
service. Of those who attended ≥7 sessions, >40% achieved a 5kg weight loss. This research shows 
that a structured weight management programme can be clinically effective for at least some patients 
with type 2 diabetes; the main challenge is getting a higher number of patients referred to and 
engaging with intervention programmes. 
Those patients who successfully lost 5kg in the first 16 weeks of the programme went on to attend for 
an average of 11.9 months. This is likely related to the large weight loss and successful weight 
maintenance in that group and is supportive of current guidelines that recommend that patients receive 
monthly counselling for at least 1 year in order to better maintain weight loss(20). The effects of weight 
loss on glycaemic control that we have found are very similar to those found by the NIH funded 
LookAHEAD study(13). There are large differences between our study and LookAHEAD: the 
lookAHEAD intervention was far more intensive, it included supervised exercise and meal 
replacements, and the population included volunteer participants in a clinical trial. This is in contrast 
with real world data from a completely free of charge weight management programme which may be 
a better representation of the general diabetes population. For those reasons LookAHEAD achieved 
weight loss in a far higher proportion of their participants, yet their results of weight loss on HbA1c 
were very similar with a change of -7mmol/mol at year 1, attenuating to -2.8mmol/mol by year 3(13) 
compared to our -7.19mmol/mol at year 1 and -1.86mmol/mol by year 3. A recent small study based 
on real-life clinic data from Boston, USA, also showed similar results of attenuation of HbA1c 
reduction over time despite maintenance of weight loss(22). The mechanisms of this attenuation in 
HbA1c are unknown and possible explanations include improved medication adherence during the 
intervention period that decreases with time, or a difference in the metabolic response to acute weight 
loss as opposed to the maintenance of lower weight in the longer term. What also remains unknown is 
the effect of this albeit temporary reduction in HbA1c on glucose-related diabetes end-points such as 
retinopathy, nephropathy and neuropathy, and also on the future trajectory of glycaemic control 
compared to those who did not lose weight. If improved glycaemic control can be achieved against a 
background of less prescribed medication in those who lose weight, then that alone suggests that 
weight management interventions may be very cost-effective in patients with type 2 diabetes. 
. The obesity paradox is a phenomenon seen in observational studies whereby people with higher BMI 
experience better health outcomes compared to those with a BMI within the normal range (20-
25kg/m2). The obesity paradox has been described in a range of disease states including type 2 
diabetes(23). Non-intentional weight loss is often cited as a potential source of bias in such analyses; 
that is, body mass being lower due to weight loss associated with a life-limiting illness or, as in the 
case of diabetes, weight loss due to poor glycaemic control. Our dataset allowed us to explore 
assumed intentionality of weight loss and its effect on HbA1c and we found that 5% weight loss in 
those who attended weight management (and therefore assumed to be intentional weight loss) results 
in a greater reduction in HbA1c than 5% weight loss in the general population with type 2 diabetes 
and co-existing obesity. This may be due to non-intentional weight loss as a result of a disease-state or 
poor glycaemic control in the general population, or a wider behavioural effect of the weight 
management programme on medication adherence. 
While the patients who successfully lost 5kg in the first 16 weeks of the weight management 
programme had weight loss maintenance and improvements in glycaemic control, they represent 
41.3% of those completing the first part of the programme and 21.7% of those attending. 11.9% of the 
eligible population (5855 out of 49137) were referred to the weight management programme, with 
many of those referred not opting in for an appointment. Clearly there are major unsolved issues 
surrounding access to weight management programmes and having access to integrated health records 
from primary care, referral systems, and weight management programmes, which allows the full 
details of these patterns to be seen; it should be remembered that those not attending are no longer an 
expense to the service. Given GCWMS is a NHS funded programme, free at the point of use and 
widely advertised to primary and secondary care clinicians, there is not the same level of commitment 
to the programme from all who are referred or start attending than would be the case in a more 
selective programme that required a specialist referral route or would cost the participant money. One 
advantage of this system is that our population is close to representative of the population of the local 
health board area which has high levels of socio-economic deprivation. However, even then there is 
an underrepresentation of men in the referred population and a higher non-completion rate from those 
who live in areas of higher socio-economic deprivation. This may be related to the structure of the 
programme, location and access; this is an issue across all weight management programmes and an 
area for the focus of future research. There is little published research with which to compare our 
research for attendance and completion as the majority of published literature is from either research-
based interventions with selected volunteers, or real-world programmes that have little or no 
information on their eligible population or those who refused referral. Other UK based interventions 
make the best comparators due to the unique set-up of the National Health Service (NHS). Ahern et 
al(24) studied 29376 patients who were referred by NHS primary care in the UK to a 12 week 
programme of Weight Watchers, of whom 22519 were first-time referrals. 11851 (57%) completed 
the programme and 6755 (29.9%) lost ≥5% body weight. The diabetes status of these patients was not 
reported but it can be assumed to be far less than half with T2DM; patients with T2DM generally lose 
less weight with weight management interventions than those without(25,26). There are many reasons 
why patients may not attend or complete weight management programmes which can include 
competing priorities like caring commitments and other health issues, or issues related to the 
programme such as venues that cannot be reached easily by public transport, or timings that exclude 
hours regularly accessible by those that work. Staff in primary care report a lack of confidence in 
raising the issue of obesity and weight management with their patients; the use of effective behaviour 
change techniques in this initial conversation may help improve attendance and completion rates(27,28). 
Our own programme is undergoing review to ensure equality of access, educating clinicians about 
discussing obesity and making referrals, and greater use of local rather than central venues where 
possible. We feel strongly that the fact that those who did lose weight maintained that weight loss and 
had clinically meaningful improvements in glycaemic control, shows the potential of weight 
management interventions in type 2 diabetes to improve clinical outcomes. Given this clinical 
potential, there is an urgent need for more research in this area to develop and deliver interventions 
that are accessible for all our patients. 
Limitations 
This study is based on data from electronic health records and therefore the major limiting issue is 
missing data. We applied strict criteria about the availability of key variables which would have been 
obtained through annual diabetes review, plus weight and age criteria to reduce the bias of 
misclassification of diabetes, and excluded 61.1% of those not referred to GCWMS and 40.7% of 
those who were referred. Given that missing data often is due to a missed annual diabetes review, and 
therefore adverse health behaviour, it may be that we biased the cohort towards a population with 
better overall diabetes management. It could be argued that this could affect the result in either 
direction due to better adherence to the intervention or a smaller potential for improvement in 
glycaemic control. 
We have shown that patients with type 2 diabetes who attended a weight management programme and 
lost weight in a real-world setting have a subsequent improvement in glycaemic control over 3 years 
of follow-up. These results are from observation of a weight management intervention and the link 
between the intervention and the resultant clinical effect cannot be deemed to be causal. However the 
results are very close to those seen in a large randomised control trial of efficacy(13) and produce 
corresponding effectiveness data. While there are still remaining issues about access, attendance and 
adherence, weight management interventions have the potential to improve clinical outcomes for 
patients with type 2 diabetes and co-existent obesity, and we need to invest in interventions, 
evaluation and improvement to maximise this potential.  
Disclosure of conflicts of interest: No authors have any conflicts of interest. 
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Figures: 
Figure 1. Data handling and classification of patients who were referred to the GCWMS. 
GC&C, Greater Glasgow and Clyde area; GCWMS, Glasgow and Clyde Weight Management Service; BMI, 
body mass index; HbA1c, glycated haemoglobin. 
Figure 2. Difference in a) mean weight, b) mean HbA1c, c) mean change in weight and d) mean change in 
HbA1c over time in patients diagnosed with type 2 diabetes and co-existent obesity in NHS Greater Glasgow 
and Clyde by referral and completion status in the Glasgow and Clyde Weight Management Service. HbA1c, 
glycated haemoglobin. 
 
Figure 3. Absolute change in insulin use over time in patients diagnosed with type 2 diabetes and co-existent 
obesity in NHS Greater Glasgow and Clyde by referral and completion status in the Glasgow and Clyde Weight 
Management Service. 
Supplemental figure 1. Mean number of unique diabetes medications prescribed to patients diagnosed with 
type 2 diabetes and co-existent obesity in NHS Greater Glasgow and Clyde by referral and completion status in 
the Glasgow and Clyde Weight Management Service. 
 
 
 
 
Table 1 Characteristics of patients diagnosed with type 2 diabetes and co-existent obesity in NHS Greater 
Glasgow and Clyde by referral status in GCWMS 
 
Not referred to WMS 
(n=19737) 
Referred to and attended 
WMS (n=1537) 
p-value 
    
Age, years 58.9 ± 9.8 57.4 ± 9.2 <0.001 
Male sex 11,062 (56.1%) 638 (41.5%) <0.001 
Ethnicity, n(%)   <0.001 
White (Scottish and other) 17,337 (88.9%) 1422 (94.7%)  
Other 2375 (12.1%) 80 (5.3%)  
SIMD score quintiles, n (%)   <0.001 
Q1 Most deprived  8975 (45.6%) 617 (40.3%)  
Q2  3709 (18.9%) 263 (17.2%)  
Q3  2441 (12.4%) 241 (15.7%)  
Q4 2158 (11.0%) 184 (12.0%)  
Q5 Least deprived 2384 (12.1%) 227 (14.8%)  
Diabetes duration, years 3.7 (0.7-8.3) 5.3 (2.1-9.6) <0.001 
Initial weight, kg* 99.1 ± 15.3 113.5 ± 23.2 <0.001 
Initial BMI, kg/m2 33.9 (31.7-37.4) 40.2 (36.1-44.8) <0.001 
Initial BMI categories, n (%)   <0.001 
30-34 kg/m2 9991 (50.6%) 198 (12.9%)  
35-39 kg/m2 6236 (31.6%) 465 (30.3%)  
40-49 kg/m2 3166 (16.0%) 680 (44.2%)  
≥50 kg/m2 344 (1.7%) 194 (12.6%)  
Systolic blood pressure, mmHg 136 ± 15 137 ± 14 0.62 
HbA1c, mmol/mol 56 (48-68) 57 (49-73) <0.001 
Total cholesterol, mmol/L 4.58 ± 1.11 4.48 ± 1.04 <0.001 
Triglycerides, mmol/L 2.0 (1.5-2.9) 2.0 (1.5-2.8) 0.038 
HDL cholesterol, mmol/L 1.11 ± 0.29 1.12 ± 0.28 0.06 
LDL cholesterol, mmol/L 2.47 ± 0.93 2.37 ± 0.88 0.002 
Any insulin, n (%) 1744 (8.8%) 132 (8.6%) 0.74 
Number of unique diabetes 
medications ** 
1 (0-2) 1 (1-2) 
<0.001 
GCWMS, Glasgow and Clyde Weight Management Service; SIMD, Scottish Index of Multiple Deprivation; BMI, 
body mass index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.  
Values are n(%), mean (standard deviation), or median (interquartile range) 
*Back calculated from BMI by using a constant height value. 
**Number of unique diabetic medications taken from nine possible categories. 
 
  
Table 2 Baseline characteristics of patients diagnosed with type 2 diabetes and co-existent obesity attending GCWMS by 
eventual completion status  
 
Non-completers 
(n=729) 
Completers 
(n=808) 
 
Unsuccessful 
(n=474) 
Successful 
(n=334) 
p-value comparing 
unsuccessful and successful 
completers 
Age, years 56.8 ± 9.4 57.9 ± 9.1 58.2 ± 8.8 0.64 
Male sex 283 (38.8%) 199 (42.0%) 156 (46.7%) 0.18 
Ethnicity, n(%)    0.99 
White (Scottish and other) 656 (92.3%) 452 (96.8%) 314 (96.9%)  
Other 55 (7.7%) 15 (3.2%) 10 (3.1%)  
SIMD score quintiles, n (%)    0.61 
Q1 Most deprived  314 (43.3%) 180 (38.1%) 123 (36.8%)  
Q2  130 (17.9%) 78 (16.5%) 55 (16.5%)  
Q3  117 (16.1%) 75 (15.9%) 49 (14.7%)  
Q4 75 (10.3%) 67 (14.2%) 42 (12.6%)  
Q5 Least deprived 90 (12.4%) 72 (15.3%) 65 (19.5%)  
Diabetes duration, years 5.4 (2.2-9.7) 5.1 (2.2-9.5) 5.3 (2.1-9.6) 0.87 
Initial weight, kg 112.3 ± 22.5* 113.2 ± 23.1 116.6 ± 24.8 0.045 
Initial BMI, kg/m2 40.1 (36.1-44.8) 39.9 (35.8-44.6) 40.7 (36.1-44.9) 0.099 
Initial BMI categories, n (%)    0.13 
30-34 kg/m2 94 (12.9%) 71 (15.0%) 33 (9.9%)  
35-39 kg/m2 222 (30.5%) 145 (30.6%) 98 (29.3%)  
40-49 kg/m2 333 (45.7%) 196 (41.4%) 151 (45.2%)  
≥50 kg/m2 80 (11.0%) 62 (13.1%) 52 (15.6%)  
Systolic blood pressure, mmHg 136 ± 13 137 ± 14 137 ± 15 0.94 
HbA1c, mmol/mol 58 (48-75) 57 (50-73) 56 (49-68) 0.06 
Total cholesterol, mmol/L 4.52 ± 1.06 4.47 ± 1.01 4.40 ± 1.03 0.39 
Triglycerides, mmol/L 2.0 (1.5-2.8) 2.0 (1.5-2.8) 1.9 (1.4-2.5) 0.12 
HDL cholesterol, mmol/L 1.11 ± 0.28 1.14 ± 0.29 1.12 ± 0.28 0.45 
LDL cholesterol, mmol/L 2.38 ± 0.87 2.36 ± 0.91 2.36 ± 0.86 0.99 
Any insulin, n (%) 66 (9.1%) 42 (8.9%) 24 (7.2%) 0.39 
Number of unique diabetes 
medications ** 
1 (1-2) 1 (1-2) 1 (0-2) 0.11 
GCWMS, Glasgow and Clyde Weight Management Service; SIMD, Scottish Index of Multiple Deprivation; BMI, body mass 
index; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.  
Values are n(%), mean (standard deviation), or median (interquartile range) 
*Back calculated from BMI by using a constant height value. 
**Number of unique diabetic medications taken from nine possible categories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Changes in key variables (95% CI) over time in patients diagnosed with type 2 diabetes and co-existent obesity in NHS Greater Glasgow and Clyde 
by referral and completion status in GCWMS 
 Not referred to 
GCWMS 
(n=19737) 
Referred to and attended GCWMS 
(n=1537) 
Total 
(n=1537) 
Non-completers 
(n=729) 
Completers 
(n=808) 
Unsuccessful 
(n=474) 
Successful 
(n=334) 
Weight, kg 
1 year change -0.57 (-0.68;-0.47) -4.23 (-4.63;-3.83) -2.74 (-3.26;-2.23) -3.33 (-4.00;-2.67) -8.66 (-9.59;-7.74) 
  n 15310 1384 649 430 305 
2 year change -0.70 (-0.83;-0.57) -4.55 (-5.06;-4.03) -3.03 (-3.83;-2.23) -3.78 (-4.55;-3.01) -8.78 (-9.87;-7.68) 
  n 14390 1309 595 424 290 
3 year change -1.00 (-1.15;-0.85) -4.64 (-5.23;-4.05) -3.26 (-4.01;-2.51) -4.26 (-5.36;-3.16) -8.03 (-9.44;-6.62) 
  n 13083 1127 504 376 247 
HbA1c mmol/mol 
1 year change -2.13 (-2.32;-1.94) -2.50 (-3.30;-1.71) -0.86 (-2.07;0.35) -1.68 (-2.99;-0.38) -7.19 (-8.83;-5.55) 
  n 17852 1466 690 455 321 
2 year change -0.90 (-1.12; -0.68) -0.64 (-1.54;0.26) 0.77 (-0.59;2.13) 0.12 (-1.46;1.70) -4.73 (-6.50;-2.96) 
  n 17067 1381 636 445 300 
3 year change 0.35 (0.10;0.59) 1.03 (-0.02;2.07) 2.02 (0.40;3.63) 1.44 (-0.34;3.21) -1.68 (-3.83;0.47) 
  n 15539 1170 531 386 253 
Change in number of unique diabetes medications 
1 year change 0.22 (0.21;0.23) 0.16 (0.12;0.20) 0.19 (0.13;0.24) 0.19 (0.13; 0.25) 0.06 (-0.14; 0.13) 
  n 19737 1537 729 474 334 
2 year change 0.32 (0.31;0.33) 0.22 (0.18;0.26) 0.26 (0.19; 0.32) 0.31 (0.24; 0.39) 0.00 (-0.84; 0.84) 
  n 19737 1491 690 470 331 
3 year change 0.33 (0.32;0.34) 0.30 (0.25;0.36) 0.38 (0.29; 0.46) 0.39 (0.29; 0.48) 0.04 (-0.07;0.14) 
  n 19737 1281 589 410 282 
Change in insulin use 
1 year net change compared to baseline 1.2% (1.0%; 1.4%) 1.7% (0.01; 2.6%) 2.5% (1.0%; 4.0%) 1.7% (0.0%; 3.3%) 0.0% (-1.1; 1.1%) 
  N on insulin/n at risk (absolute %) 1975/19737 (10.0%) 158/1537 (10.3%) 84/729 (11.5%) 50/474 (10.6%) 24/334 (7.2%) 
      
2 year net change compared to baseline 1.9% (1.7%; 2.2%) 3.3% (2.2%; 4.4%) 4.5% (2.7%; 6.3%) 3.4% (1.2% 5.6%) 0.6% (-1.1%; 2.4%) 
  N on insulin/n at risk (absolute %) 2127/19737 (10.8%) 174/1491 (11.7%) 90/690 (13.0%) 58/470 (12.3%) 26/331 (7.9%) 
 
3 year net change compared to baseline 
 
2.7% (2.4%; 3.0%) 
 
5.0% (3.6%; 6.4%) 
 
7.0% (4.6% 9.3%) 
 
4.4% (1.9% 6.8%) 
 
1.8% (-1.1% 4.6%) 
  N on insulin/n at risk (absolute %) 2280/19737 (11.6%) 178/1281 (13.9%) 95/589 (16.1%) 55/410 (13.4%) 28/282 (9.9%) 
GCWMS, Glasgow and Clyde Weight Management Service; HbA1c, glycated haemoglobin. Data are expressed as arithmetic mean ± SD, 95% confidence intervals or n. 
Table 4 Adjusted effect of attending GCWMS programme and successfully losing 5kg compared to non-
completers and unsuccessful completers 
 Effect estimate 95% CI p-value 
HbA1c, mmol/mol    
   1 year change (n=1432) -6.62 -8.19;-5.04 <0.001 
   2 year change (n=1351) -5.70 -7.49;-3.92 <0.001 
   3 year change (n=1146) -3.67 -5.82;-1.51 0.001 
Weight, kg    
   1 year change (n=1352) -5.43 -6.39;-4.47 <0.001 
   2 year change (n=1280) -4.85 -5.99;-3.71 <0.001 
   3 year change (n=1106) -3.61 -5.00;-2.20 <0.001 
Unique diabetes medications use*    
   1 year change (n=1497) -0.13 -0.20;-0.05 0.001 
   2 year change (n=1453) -0.28 -0.36;-0.19 <0.001 
   3 year change (n=1254) -0.34 -0.45;-0.23 <0.001 
Insulin use (Odds ratio)    
 1 year use (n=1497) 0.42 0.18; 0.97 0.042 
 2 year use (n=1453) 0.40 0.20; 0.83 0.014 
 3 year use (n=1254) 0.54 0.25; 1.17 0.12 
HbA1c, glycated haemoglobin.  
NB HbA1c, weight & diabetes medication are absolute values; Insulin use is odds ratio. 
*Number of unique diabetic medications from nine possible categories. 
Model adjusted for age, sex, ethnicity, SIMD, time since T2DM diagnosis, baseline HbA1c, weight, BMI, diabetes 
medication and insulin use. 
 Table 5 Adjusted effect of 5% weight loss on difference in HbA1C  after 2 years stratified by GCWMS 
status 
 Effect estimate 95% CI p-value 
Change in HbA1c, mmol/mol    
   Not referred (n=15,000) -0.50 -0.69;-0.31 <0.001 
   Non-completer (n=566) -1.32 -2.24;-0.41 <0.001 
   Completer (n=677) -2.49 -3.53;-1.46 <0.001 
Model adjusted for age, sex, ethnicity, SIMD, time since T2DM diagnosis, baseline HbA1c, weight, BMI, 
diabetes medication and insulin use. p for interaction <0.001.  
Table 6 Attendance and weight outcomes of patients diagnosed with type 2 diabetes and co-existent 
obesity in NHS Greater Glasgow and Clyde by completion status in GCWMS 
 
Total attenders 
(n=1537) 
Non-completers 
(n=729) 
Completers 
(n=808) 
Unsuccessful 
(n=474) 
Successful 
(n=334) 
Phase I:     
Time attended, months* 3.7 (2.3-3.7) 1.8 (0.9-3.2) 3.7 (3.7-4.1) 3.7 (3.7-3.7) 
n 1387 582 471 334 
Last weight recorded, kg 110.5 ± 23.0 110.9 ± 22.7 111.3 ± 23.3 108.2 ± 23.3 
n 1537 729 474 334 
Change in weight, kg* -3.27 ± 4.08 -1.55 ± 2.89 -1.74 ± 2.30 -8.44 ± 3.45 
n 1392 584 474 334 
Total programme:     
Time attended, months* 5.5 (2.3-12.4) 1.8 (0.9-3.7) 7.4 (4.6-14.9) 11.9 (7.1-17.3) 
n 1387 582 471 334 
Last weight recorded, kg 109.8 ± 22.9 110.8 ± 22.7 110 ± 23.2 106.7 ± 22.8 
n 1537 729 474 334 
Change in weight, kg* -4.01 ± 6.29 -1.72 ± 3.32 -2.69 ± 4.71 -9.90 ± 8.24 
n 1391 584 473 334 
Data are expressed as arithmetic mean ± standard deviation. P≤0.05 regarded as statistically significant. 
*Only for those who attended >1 session. 
Supplement table 1 Adjusted effect of attending GCWMS programme and successfully losing 5kg compared 
to non-completers and unsuccessful completers 
 Odds ratio 95% CI p-value 
GLP-1 agonist use    
 1 year use (n=1497) 0·60 0·35; 1.03 0·063 
 2 year use (n=1453) 0·70 0·45; 1.09 0·12 
 3 year use (n=1254) 0·50 0·32; 0.80 0·003 
    
DPP-4 inhibitor use    
 1 year use (n=1497) 0·83 0·54; 1.26 0·38 
 2 year use (n=1453) 0·54 0·36; 0.83 0.004 
 3 year use (n=1254) 0·48 0·31; 0.75 0·001 
Model adjusted for age, sex, ethnicity, SIMD, time since T2DM diagnosis, baseline HbA1c, weight, BMI, diabetes 
medication number, baseline insulin, sodium/glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-
1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitor use. 
Note: SGLT2 inhibitor use was too rare to model over the timeframe of this study 
 




